BACKGROUND/ OBJECTIVE: Improved understanding of renal cell carcinomas (RCC) and recent contributions in the field of RCC biology led to the development of a novel class of drugs, i.e. multiple-kinase inhibitors, targeting growth factor receptors (e.g. sorafenib). Sorafenib has proven significant benefit in terms of progression-free survival in a phase II trial in RCC patients. A subsequent randomized phase III study (Treatment Approaches in Renal Cancer Global Evaluation Trial) confirmed the significantly prolonged progression-free survival and improvement in the quality of life compared to patients receiving placebo. In the USA and Europe, sorafenib has been approved for the treatment of advanced RCC. PATIENTS: Two RCC patients on chronic hemodialysis were treated with sorafenib. RESULTS: Both patients responded to sorafenib treatment. Apart from high blood pressure, a major adverse effect of sorafenib treatment, treatment was well tolerated, in agreement with previous results. CONCLUSION: The results of our study confirm the beneficial effect of sorafenib in the treatment of RCC in our 2 patients on dialysis. (c) 2008 S. Karger AG, Basel.
RCT Entities:
BACKGROUND/ OBJECTIVE: Improved understanding of renal cell carcinomas (RCC) and recent contributions in the field of RCC biology led to the development of a novel class of drugs, i.e. multiple-kinase inhibitors, targeting growth factor receptors (e.g. sorafenib). Sorafenib has proven significant benefit in terms of progression-free survival in a phase II trial in RCCpatients. A subsequent randomized phase III study (Treatment Approaches in Renal Cancer Global Evaluation Trial) confirmed the significantly prolonged progression-free survival and improvement in the quality of life compared to patients receiving placebo. In the USA and Europe, sorafenib has been approved for the treatment of advanced RCC. PATIENTS: Two RCCpatients on chronic hemodialysis were treated with sorafenib. RESULTS: Both patients responded to sorafenib treatment. Apart from high blood pressure, a major adverse effect of sorafenib treatment, treatment was well tolerated, in agreement with previous results. CONCLUSION: The results of our study confirm the beneficial effect of sorafenib in the treatment of RCC in our 2 patients on dialysis. (c) 2008 S. Karger AG, Basel.
Authors: F J Afonso; U Anido; O Fernández-Calvo; S Vázquez-Estévez; L León; M Lázaro; M Ramos; L Antón-Aparicio Journal: Clin Transl Oncol Date: 2013-02-12 Impact factor: 3.405
Authors: Javier Puente; Xavier García Del Muro; Álvaro Pinto; Nuria Láinez; Emilio Esteban; José Ángel Arranz; Enrique Gallardo; María José Méndez; Pablo Maroto; Enrique Grande; Cristina Suárez Journal: Target Oncol Date: 2016-04 Impact factor: 4.493